DK1027053T3 - Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser - Google Patents

Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser

Info

Publication number: DK1027053T3
Authority: DK; Denmark
Prior art keywords: administration; patient; cyclosporin; tacrolimus; pps
Prior art date: 1997-10-09

Application number

DK98952186T

Other languages

English (en)

Inventor

Gary E Striker

Lilliane Striker

Kenneth H Kortright

Original Assignee

Ivax Research Inc

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-09

Filing date

1998-10-09

Publication date

2004-09-06

1998-10-09 Application filed by Ivax Research Inc, Us Health filed Critical Ivax Research Inc

2004-09-06 Application granted granted Critical

2004-09-06 Publication of DK1027053T3 publication Critical patent/DK1027053T3/da

Links

229930182912 cyclosporin Natural products 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 4
206010029155 Nephropathy toxic Diseases 0.000 title abstract 2
231100000417 nephrotoxicity Toxicity 0.000 title abstract 2
230000007694 nephrotoxicity Effects 0.000 title abstract 2
108010036941 Cyclosporins Proteins 0.000 title 1
229940043138 pentosan polysulfate Drugs 0.000 abstract 4
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 3
229930105110 Cyclosporin A Natural products 0.000 abstract 3
108010036949 Cyclosporine Proteins 0.000 abstract 3
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 3
229960001265 ciclosporin Drugs 0.000 abstract 3
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 3
229960001967 tacrolimus Drugs 0.000 abstract 3
239000008194 pharmaceutical composition Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
230000037396 body weight Effects 0.000 abstract 1
238000011260 co-administration Methods 0.000 abstract 1
238000002650 immunosuppressive therapy Methods 0.000 abstract 1
231100000268 induced nephrotoxicity Toxicity 0.000 abstract 1
230000008085 renal dysfunction Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Cephalosporin Compounds (AREA)

DK98952186T 1997-10-09 1998-10-09 Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser DK1027053T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6294797P	1997-10-09	1997-10-09

Publications (1)

Publication Number	Publication Date
DK1027053T3 true DK1027053T3 (da)	2004-09-06

Family

ID=22045901

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98952186T DK1027053T3 (da)	1997-10-09	1998-10-09	Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser

Country Status (23)

Country	Link
US (1)	US6187745B1 (da)
EP (1)	EP1027053B1 (da)
JP (1)	JP2001519392A (da)
KR (1)	KR100515196B1 (da)
CN (1)	CN1154492C (da)
AT (1)	ATE269098T1 (da)
AU (1)	AU748495B2 (da)
BR (1)	BR9813860A (da)
CA (1)	CA2304374A1 (da)
CZ (1)	CZ297440B6 (da)
DE (1)	DE69824619T2 (da)
DK (1)	DK1027053T3 (da)
ES (1)	ES2221714T3 (da)
HU (1)	HUP0003904A3 (da)
IL (1)	IL135235A0 (da)
NO (1)	NO20001828L (da)
NZ (1)	NZ503493A (da)
PL (1)	PL191993B1 (da)
PT (1)	PT1027053E (da)
RU (1)	RU2191020C2 (da)
SK (1)	SK285332B6 (da)
UA (1)	UA65587C2 (da)
WO (1)	WO1999018961A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001230994A1 (en) *	2000-01-19	2001-07-31	The United States of America, represented by The Secretary, Department of Health & Human Services	Use of pentosan polysulfate to treat certain conditions of the prostate
US6613083B2 (en) *	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
EP2116228A1 (en) *	2001-10-19	2009-11-11	Isotechnika Inc.	Novel cyclosporin analog microemulsion preconcentrates
PL372902A1 (en) *	2002-04-16	2005-08-08	Astellas Pharma Inc.	New use
PL1748781T3 (pl)	2004-05-27	2013-05-31	Baxter Int	Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów
AU2009284393B2 (en)	2008-08-22	2014-09-25	Takeda Pharmaceutical Company Limited	Methods for treating bleeding disorders
US8632991B2 (en)	2010-01-14	2014-01-21	Baxter International Inc.	Methods and compositions for treating bleeding disorders
US8871741B2 (en) *	2010-01-15	2014-10-28	Icahn School Of Medicine At Mount Sinai	Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate
CN102327282A (zh) *	2010-09-01	2012-01-25	吴洪	戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
EP3417865A1 (en)	2011-07-19	2018-12-26	Baxalta GmbH	Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
WO2013052380A2 (en) *	2011-10-05	2013-04-11	Allergan, Inc.	Compositions for enhancing nail health
US9417251B2 (en)	2012-08-14	2016-08-16	Baxalta GmbH	Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
KR101760510B1 (ko)	2014-12-18	2017-07-21	가톨릭대학교 산학협력단	메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) *	2014-12-18	2016-06-23	가톨릭대학교 산학협력단	메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
RU2680098C1 (ru) *	2015-06-12	2019-02-15	Вишал Джаджодиа Свати	Лекарственное средство, содержащее пентозанполисульфат натрия, для использования в лечении обструкции выходного отверстия мочевого пузыря и/или симптомов нижних мочевых путей

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3843241A1 (de) *	1988-12-22	1990-06-28	Skrezek Christian	Nephroprotektive infusionsloesung
EP0466315A3 (en)	1990-05-30	1992-07-01	Larrian Gillespie	Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en)	1990-06-11	1993-04-20	Du Pont Merck Pharmaceutical Company	Treatment of organ transplantation rejection
GB9116836D0 (en) *	1991-08-05	1991-09-18	Sandoz Ltd	Organic compounds
US5605938A (en) *	1991-05-31	1997-02-25	Gliatech, Inc.	Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
RU2027471C1 (ru) *	1992-04-14	1995-01-27	Северо-Кавказский горно-металлургический институт	Способ очистки суспензий и вибрационный фильтр-сгуститель для его осуществления
IT1277147B1 (it) *	1995-01-20	1997-11-04	Sigma Tau Ind Farmaceuti	Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) *	1995-02-03	1996-08-13	L T T Kenkyusho:Kk	腎不全治療剤
US5643892A (en)	1995-06-07	1997-07-01	Baker Norton Pharmaceuticals, Inc.	Method of treating chronic progressive vascular diseases

1998
- 1998-09-10 UA UA2000041980A patent/UA65587C2/uk unknown
- 1998-10-01 US US09/168,974 patent/US6187745B1/en not_active Expired - Fee Related
- 1998-10-09 JP JP2000515596A patent/JP2001519392A/ja active Pending
- 1998-10-09 KR KR10-2000-7003305A patent/KR100515196B1/ko not_active Expired - Fee Related
- 1998-10-09 CN CNB988100363A patent/CN1154492C/zh not_active Expired - Fee Related
- 1998-10-09 BR BR9813860-0A patent/BR9813860A/pt not_active Application Discontinuation
- 1998-10-09 ES ES98952186T patent/ES2221714T3/es not_active Expired - Lifetime
- 1998-10-09 IL IL13523598A patent/IL135235A0/xx not_active IP Right Cessation
- 1998-10-09 AT AT98952186T patent/ATE269098T1/de not_active IP Right Cessation
- 1998-10-09 AU AU97943/98A patent/AU748495B2/en not_active Ceased
- 1998-10-09 DE DE69824619T patent/DE69824619T2/de not_active Expired - Fee Related
- 1998-10-09 PT PT98952186T patent/PT1027053E/pt unknown
- 1998-10-09 PL PL339774A patent/PL191993B1/pl not_active IP Right Cessation
- 1998-10-09 CZ CZ20001274A patent/CZ297440B6/cs not_active IP Right Cessation
- 1998-10-09 EP EP98952186A patent/EP1027053B1/en not_active Expired - Lifetime
- 1998-10-09 CA CA002304374A patent/CA2304374A1/en not_active Abandoned
- 1998-10-09 HU HU0003904A patent/HUP0003904A3/hu unknown
- 1998-10-09 RU RU2000111495/14A patent/RU2191020C2/ru not_active IP Right Cessation
- 1998-10-09 WO PCT/US1998/021313 patent/WO1999018961A1/en not_active Ceased
- 1998-10-09 NZ NZ503493A patent/NZ503493A/en unknown
- 1998-10-09 DK DK98952186T patent/DK1027053T3/da active
- 1998-10-09 SK SK467-2000A patent/SK285332B6/sk unknown
2000
- 2000-04-07 NO NO20001828A patent/NO20001828L/no unknown

Also Published As

Publication number	Publication date
KR100515196B1 (ko)	2005-09-16
EP1027053B1 (en)	2004-06-16
ATE269098T1 (de)	2004-07-15
SK285332B6 (sk)	2006-11-03
CN1154492C (zh)	2004-06-23
BR9813860A (pt)	2001-03-20
ES2221714T3 (es)	2005-01-01
HUP0003904A1 (hu)	2001-08-28
KR20010030749A (ko)	2001-04-16
NO20001828D0 (no)	2000-04-07
CN1275080A (zh)	2000-11-29
RU2191020C2 (ru)	2002-10-20
NZ503493A (en)	2001-11-30
PT1027053E (pt)	2004-09-30
US6187745B1 (en)	2001-02-13
WO1999018961A1 (en)	1999-04-22
CZ297440B6 (cs)	2006-12-13
SK4672000A3 (en)	2001-09-11
EP1027053A4 (en)	2002-05-22
CZ20001274A3 (cs)	2001-12-12
HK1026845A1 (en)	2000-12-29
PL339774A1 (en)	2001-01-02
JP2001519392A (ja)	2001-10-23
UA65587C2 (en)	2004-04-15
DE69824619T2 (de)	2005-06-23
IL135235A0 (en)	2001-05-20
CA2304374A1 (en)	1999-04-22
EP1027053A1 (en)	2000-08-16
NO20001828L (no)	2000-05-15
HUP0003904A3 (en)	2006-06-28
PL191993B1 (pl)	2006-08-31
DE69824619D1 (de)	2004-07-22
AU748495B2 (en)	2002-06-06
AU9794398A (en)	1999-05-03

Publication	Publication Date	Title
NO20001828L (no)	2000-05-15	Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus
CO5251419A1 (es)	2003-02-28	Composiciones nanoparticuladas de eplerenona
WO2005065069A3 (en)	2005-09-22	Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2188782T3 (es)	2003-07-01	Formulaciones farmaceuticas que contienen darifenacina.
BG106906A (bg)	2003-04-30	Пуринови производни
CO5261582A1 (es)	2003-03-31	Composiciones de valdecoxib
ATE424810T1 (de)	2009-03-15	Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
JP2002523370A5 (da)	2006-08-17
KR910019618A (ko)	1991-12-19	발기부전증 치료용 제약 조성물
MY111260A (en)	1999-10-30	Pharmaceutical composition for the treatment of nicotine dependence
EP0375628A3 (en)	1991-08-14	Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
KR19980701720A (ko)	1998-06-25	세스키테르펜 락톤 및 비타민 b 복합체를 함유하는 편두통 및 기타 질환 치료용 복합약
MY124465A (en)	2006-06-30	Reduction of infarct volume using citicoline
CA2537748A1 (en)	2005-03-17	Use of telmisartan for the prevention of vascular headache
KR900011461A (ko)	1990-08-01	트립스타틴을 유효성분으로 하는 치료제
EP0190851B1 (en)	1990-01-03	Improved antiinflammatory composition
NO974486L (no)	1997-09-29	Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
KR890004705A (ko)	1989-05-09	항바이러스성 제제
BE1002255A5 (fr)	1990-11-06	Medicaments.
NL8105635A (nl)	1983-07-01	Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking.
CA2559239A1 (en)	2005-10-27	Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night
BE1002256A3 (fr)	1990-11-06	Medicaments.
NZ315632A (en)	1999-11-29	Process for preparing solid dosage forms of very low-dose drugs comprising admixing 1-3% by weight of carrier particles with a solution of drug in water
RU99112967A (ru)	2001-04-27	Способ лечения и профилактики дизентерии свиней
ATE91890T1 (de)	1993-08-15	Herstellung eines arzneimittels gegen arthritis und rheumatismus.